Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exelixis Has Renewed Momentum Heading Into 2021

Executive Summary

The approval of Cabometyx in combination with Opdivo as a first-line treatment for RCC will power substantial growth at Exelixis into 2022.

You may also be interested in...



EU Decision Time On Expanded Use Of BMS/Ipsen Pharma Cancer Drug Combo

The European Medicines Agency may decide this week on a dozen requests by companies seeking new uses of their approved drugs.

Keeping Track: 2021’s First Novel Approvals Go To HIV And Heart Failure Therapies Opdivo Starts Year With A Bang

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Exelixis’ Cabozantinib Cleared For Kidney Cancer, With Competitive Labeling

Company plans to launch within two weeks, priced at a premium to competing drugs in kidney cancer.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel